Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New proton therapy trial aims to reduce side effects in nasopharyngeal cancer

NCT ID NCT07578727

Disease control Sponsor: Guangzhou Concord Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This Phase III trial will compare proton beam radiotherapy with standard photon radiotherapy in 504 patients with non-metastatic nasopharyngeal carcinoma. The goal is to see if proton therapy reduces toxic side effects and improves survival. Participants will be randomly assigned to one of the two radiation types and followed for at least three years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Proton beam radiotherapy (ProBeam system)
What this could lead to
If successful, proton therapy could become a standard treatment for nasopharyngeal cancer, offering fewer side effects and better survival than current photon radiotherapy.
What could go wrong
This is an early-stage Phase III trial that has not yet started recruiting. Proton therapy is more expensive and less available, and results may not show a clear advantage over existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 504 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosed by histology and/or cytology as non-keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, i.e., WHO type II or III). 2. Clinical stage: T1-4N0-3M0, I-III stage (AJCC 9th edition). 3. Age: ≥ 18 years old, ≤ 70 years old. 4. Gender: No restrictions. 5. ECOG ≤ 1. 6. Good organ function: Normal bone marrow function: WBC ≥ 4×109/L, Platelet ≥ 100×109/L, HGB ≥ 90g/L Total bilirubin, AST, ALT ≤ 2.0× upper limit of normal value; Creatinine clearance rate ≥ 60ml/min or Creatinine ≤ 1.5× upper limit of normal value. 7. The patient has signed the informed consent form and is willing and able to comply with the study visit schedule, treatment plan, laboratory tests and other research procedures. Exclusion Criteria: 1. The patient has a poor general condition and is in a state of poor health; or the patient has already experienced metastasis. 2. The patient has an uncontrolled severe infectious disease. 3. The patient has severe diseases or complications in the heart, lungs, liver, kidneys or other systems, and the investigator judges that they cannot complete the clinical trial. 4. There are implants such as artificial ears or dentures within the radiotherapy range, and the investigator judges that they are not suitable for proton therapy. 5. The patient has a history of radiotherapy in the head and neck region. 6. The patient has mental illness, drug abuse or alcohol dependence.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma (NPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal carcinoma (NPC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Varian Probeam

    Guangzhou, Guangdong, China

  • Varian Probeam

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.